Ionis Pharmaceuticals. (2018). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington’s Disease ClinicalTrials.gov.

See more from authors: Ionis Pharmaceuticals

References and models cited by this paper
References and models that cite this paper

Goodliffe JW et al. (2018). Differential changes to D1 and D2 medium spiny neurons in the 12-month-old Q175+/- mouse model of Huntington's Disease. PloS one. 13 [PubMed]

This website requires cookies and limited processing of your personal data in order to function. By continuing to browse or otherwise use this site, you are agreeing to this use. See our Privacy policy and how to cite and terms of use.